| Feb 3 2025 |
REBO Quarterly: 2024 in Retrospect |
K&L Gates LLP |
| Feb 3 2025 |
Tariffs on Mexico, Canada Paused for 30 Days |
Miller Canfield |
| Feb 3 2025 |
Wearable Technologies and Employment Risks – EEOC Issues New Guidance |
Sheppard, Mullin, Richter & Hampton LLP |
| Feb 3 2025 |
New Tariffs on U.S. Imports from Canada, Mexico, and China |
Polsinelli PC |
| Feb 3 2025 |
The Trade War Begins with Canada, China, and Mexico |
Miller Canfield |
| Feb 3 2025 |
FDA & OHRP Draft Guidance: Including Tissue Biopsies in Clinical Trials |
Foley & Lardner LLP |
| Jan 31 2025 |
EC Launches Biotech and Biomanufacturing Hub to Support Innovative Companies |
Bergeson & Campbell, P.C. |
| Jan 31 2025 |
2025 Top-of-Mind Issues for Life Sciences Companies |
Sheppard, Mullin, Richter & Hampton LLP |
| Jan 31 2025 |
McDermott+ Check-Up: January 31, 2025 |
McDermott Will & Emery |
| Jan 31 2025 |
FDA Releases Draft Guidance on AI-Enabled Medical Devices |
Greenberg Traurig, LLP |
| Jan 31 2025 |
Federal Appeals Court Holds New Jersey’s Cannabis Law Provides No Private Right of Action |
Jackson Lewis P.C. |
| Jan 30 2025 |
Bottling the Truth: Equivalence and Reverse Equivalence |
McDermott Will & Emery |
| Jan 29 2025 |
FDA Develops Strategy to Prevent Adulteration of Berries with Enteric Viral Infections |
Keller and Heckman LLP |
| Jan 29 2025 |
President Trump Enacts Regulatory Freeze and Halts Public Communications for Federal Agencies |
Keller and Heckman LLP |
| Jan 29 2025 |
Florida HR Considerations: Marijuana in the Workplace |
Proskauer Rose LLP |
| Jan 28 2025 |
HHS-OIG Issues Favorable Opinion on Drug Manufacturer’s Free Genetic Testing, Counseling for Patients |
Barnes & Thornburg LLP |
| Jan 28 2025 |
FDA Broadens Oversight of Lab-Developed Tests |
Womble Bond Dickinson (US) LLP |
| Jan 27 2025 |
FDA Dumps Trio of Device-Related Guidances Prior to Administration Change |
Sheppard, Mullin, Richter & Hampton LLP |
| Jan 27 2025 |
Never Get Out of This Maze? Or a Path Forward for Alabama’s Medical Cannabis Program? |
Bradley Arant Boult Cummings LLP |
| Jan 25 2025 |
China’s State Council Releases Antitrust Guidelines for the Pharmaceutical Sector Covering Reverse Payments and Evergreening |
Schwegman, Lundberg & Woessner, P.A. |
| Jan 24 2025 |
AAFCO Approves New Regulatory Pathway for Animal Food Ingredients |
Keller and Heckman LLP |
| Jan 24 2025 |
4th Circuit Upholds Virginia “Total Hemp Law” |
Keller and Heckman LLP |
| Jan 24 2025 |
Swing and a Miss: The Government Strikes Out in Pharmacy Executive Kickback Trial |
Polsinelli PC |
| Jan 24 2025 |
Prop 65 Year-End Highlights: 2024’s Key Regulatory Changes, Legal Battles, and Enforcement Trends |
Sheppard, Mullin, Richter & Hampton LLP |
| Jan 24 2025 |
McDermott+ Check-Up: January 24, 2025 |
McDermott Will & Emery |
| Jan 23 2025 |
Will 2025 Continue Circuit Court Harmony in Nationwide Litigation Involving State Law Hemp Legislation, or Will a Circuit Split Emerge? |
Bradley Arant Boult Cummings LLP |
| Jan 23 2025 |
FDA Issues First Marketing Authorization for Oral Nicotine Pouches |
Keller and Heckman LLP |
| Jan 23 2025 |
What Every Multinational Company Should Know About … Managing Import Risks Under the New Trump Administration (Part II): The Implications of President Trump’s “America First Trade Memorandum” |
Foley & Lardner LLP |
| Jan 22 2025 |
This Week in 340B: January 14 – 20, 2025 |
McDermott Will & Emery |
| Jan 22 2025 |
When Life Gives you Lemons….Thatchers Successful as Court of Appeal Finds Aldi Copycat Products Amount to Trade Mark Infringement in the UK |
K&L Gates LLP |
| Jan 22 2025 |
Mexico 2025: Foreign Trade Outlook | What to Expect in Terms of Foreign Trade? |
Foley & Lardner LLP |
| Jan 21 2025 |
At Long Last, DEA’s Remote Prescribing Rules 2.0 Are (Really) Here! (Pending Further Consideration by the Incoming Administration . . .) |
Epstein Becker & Green, P.C. |
| Jan 21 2025 |
New TTB Standard of Fill No Place for Kegged Cocktails |
Norris McLaughlin P.A. |
| Jan 21 2025 |
Supreme Court Update: Royal Canin U.S.A., Inc. v. Wullschleger (No. 23-677) |
Wiggin and Dana LLP |
| Jan 21 2025 |
DEA Unveils Long-Overdue Special Registration for Telemedicine in Proposed Rule |
Foley & Lardner LLP |
